David Hutton

  • University of Michigan
  • Professor, Health Sciences
  • United States

My Publications

Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, n...

  • Journal of Medical Economics
  • January 2019

Switching To Less Expensive Blindness Drug Could Save Medicare Part B $18 Billion Over ...

  • Health Affairs
  • June 2014